StockNews.AI
SIGA
StockNews.AI
110 days

SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results

1. SIGA will host a business update on May 8, 2025. 2. CEO Diem Nguyen and CFO Daniel Luckshire will participate in the call. 3. TPOXX® is approved in the U.S. and Canada for smallpox treatment. 4. SIGA focuses on treatments for severe infectious diseases like orthopoxviruses. 5. Webcast available on SIGA's Investor Relations website.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming call may reveal strategic developments or financial updates that positively impact market sentiment, similar to past earnings reports where positive news often led to price increases.

How important is it?

The business update promises insights that could enhance investor confidence and potentially increase demand for SIGA’s products.

Why Short Term?

The webcast scheduled for May 8 may influence stock price immediately following the announcement of new information or forecasts.

Related Companies

Siga Technologies Inc. (SIGA)Moderna Inc. (MRNA)Novavax Inc. (NVAX)
May 01, 2025 07:30 ET  | Source: SIGA Technologies Inc. NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 8, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1160299. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com. Contacts: Suzanne Harnett sharnett@siga.com    and   InvestorsMediaJennifer Drew-Bear, Edison GroupJdrew-bear@edisongroup.comHolly Stevens, CG Life hstevens@cglife.com

Related News